<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503527</url>
  </required_header>
  <id_info>
    <org_study_id>DBHP-001-CEN</org_study_id>
    <nct_id>NCT02503527</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy</brief_title>
  <official_title>Effects of a Diabetes-specific Tube Feed on Glycemic Variability in Critically Ill Patients During Insulin Blood Glucose Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OE Clinical Trial Center (KKS) Universität Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Medical Research - Partner GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>dsh statistical services GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a diabetes-specific tube&#xD;
      feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically&#xD;
      ill patients receiving insulin treatment for blood glucose management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose variability (within patient standard deviation of blood glucose values per day)</measure>
    <time_frame>At Day 3 of intervention or the day prior to switch from intravenous to subcutaneous insulin administration, whichever comes first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>Days 2, 4 and 5 of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to switch from intravenous to subcutaneous insulin administration</measure>
    <time_frame>Days 1-6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirements in IU per day</measure>
    <time_frame>Days 1 - 6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose levels</measure>
    <time_frame>Days 1 - 6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Days 1, 6, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between target and given enteral nutrition (Compliance)</measure>
    <time_frame>Days 2-6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral and subcutaneous microdialysis: glucose</measure>
    <time_frame>Days 1 - 6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral and subcutaneous microdialysis: lactate/pyruvate ratio</measure>
    <time_frame>Days 1 - 6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-gastrointestinal complications (AEs) to enteral nutrition and application</measure>
    <time_frame>Days 2-6, daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal intolerance (AEs, complications)</measure>
    <time_frame>Days 2-6, daily</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Diben 1.5 kcal HP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresubin HP Energy Fibre (1.5 kcal)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diben 1.5 kcal HP</intervention_name>
    <description>Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) &gt; 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).</description>
    <arm_group_label>Diben 1.5 kcal HP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresubin HP Energy Fibre (1.5 kcal)</intervention_name>
    <description>Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) &gt; 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).</description>
    <arm_group_label>Fresubin HP Energy Fibre (1.5 kcal)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with spontaneous aneurysmal subarachnoid hemorrhage (SAH) defined according&#xD;
             to Hunt and Hess scale grade HH5&#xD;
&#xD;
          -  Requiring mechanical ventilation in the ICU at the time of enrolment&#xD;
&#xD;
          -  Enteral nutrition (EN) in the ICU at time of enrolment&#xD;
&#xD;
               -  If enrolment on day 3 of ICU stay, EN equal to or larger than 80% of total&#xD;
                  calories in case of supplementary parenteral nutrition (PN) with anticipated 100%&#xD;
                  EN as of day 4 to 8 of ICU stay&#xD;
&#xD;
               -  If enrolment on day 4 of ICU stay, 100% EN planned for at least 5 days from the&#xD;
                  time of enrolment&#xD;
&#xD;
          -  Patients expected to stay in the ICU for at least 5 days following enrolment&#xD;
&#xD;
          -  Age 18 - 75 years&#xD;
&#xD;
          -  Glycemic control with intravenous insulin therapy to maintain a target glucose range&#xD;
             between 110 mg/dL and 150 mg/dL (6.1 and 8.3 mmol/l)&#xD;
&#xD;
          -  Informed consent according to local regulations for decisionally impaired subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with septic shock at time of enrolment&#xD;
&#xD;
          -  Participation in a clinical trial with any investigational product within 4 weeks&#xD;
             before study&#xD;
&#xD;
          -  Patients requiring a fibre free diet&#xD;
&#xD;
          -  Total or supplementary parenteral nutrition (&gt; 20% of total calories)&#xD;
&#xD;
          -  Known or suspected intolerance or allergy to any component of the study product(s),&#xD;
             e.g. galactosemia&#xD;
&#xD;
          -  Gastrectomy&#xD;
&#xD;
          -  Postpyloric nutrition&#xD;
&#xD;
          -  Any clinical condition not allowing enteral nutrition (e.g. emesis, severe reflux,&#xD;
             severe diarrhea)&#xD;
&#xD;
          -  Known severe heart failure (NYHA class 4)&#xD;
&#xD;
          -  Liver insufficiency / failure (male: ALAT &gt; 150 U/l; female: ALAT &gt; 120 U/l)&#xD;
&#xD;
          -  Acute kidney failure (blood creatinine &gt; 2.5 mg/dl)&#xD;
&#xD;
          -  Body Mass Index &lt; 18 or &gt; 35 kg/m²&#xD;
&#xD;
          -  Known or suspicion of drug abuse&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Patients with diabetes mellitus type I&#xD;
&#xD;
        Exclusion After Enrolment (Withdrawal of Subjects)&#xD;
&#xD;
          -  Start of PN with more than 20% of total given energy amount/ day&#xD;
&#xD;
          -  Insulin infusion stopped unexpectedly for &gt; 12h for non-nutritional reasons&#xD;
&#xD;
          -  Discharge from ICU&#xD;
&#xD;
          -  Intolerable AEs&#xD;
&#xD;
          -  Major protocol violation&#xD;
&#xD;
          -  Withdrawal of informed consent&#xD;
&#xD;
          -  Discontinuation of study treatment for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronny Beer, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck, Department of Neurology, Neurocritical Care Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John F. Stover, Prof. Dr. med.</last_name>
    <phone>+49 6172 686</phone>
    <phone_ext>4598</phone_ext>
    <email>john.stover@fresenius-kabi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Benzing, PhD</last_name>
    <phone>+49 6172 608</phone>
    <phone_ext>7709</phone_ext>
    <email>steffen.benzing@fresenius-kabi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. De Beer, PD Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enteral nutrition</keyword>
  <keyword>Tube feeding</keyword>
  <keyword>Diet, carbohydrate-restricted</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Aneurysmal Subarachnoid Hemorrhage</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

